Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_assertion type Assertion NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_head.
- NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_assertion description "[Bcl-2 antisense oligonucleotide therapy in combination with rituximab may represent a promising nontoxic and effective targeted therapy for EBV-associated lymphoproliferative diseases such as PTLD and ARL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_provenance.
- NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_assertion evidence source_evidence_literature NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_provenance.
- NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_assertion SIO_000772 12738752 NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_provenance.
- NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_assertion wasDerivedFrom befree-2016 NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_provenance.
- NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_assertion wasGeneratedBy ECO_0000203 NP393723.RAy1t2FfYesNk1Jof3rBQyryi-MhSIUxr18CGK8P4quPg130_provenance.